These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 15851915)

  • 1. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.
    Bergshoeff AS; Fraaij PL; Ndagijimana J; Verweel G; Hartwig NG; Niehues T; De Groot R; Burger DM
    J Acquir Immune Defic Syndr; 2005 May; 39(1):63-8. PubMed ID: 15851915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
    van der Lee M; Verweel G; de Groot R; Burger D
    Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.
    Hsu A; Isaacson J; Brun S; Bernstein B; Lam W; Bertz R; Foit C; Rynkiewicz K; Richards B; King M; Rode R; Kempf DJ; Granneman GR; Sun E
    Antimicrob Agents Chemother; 2003 Jan; 47(1):350-9. PubMed ID: 12499212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.
    King JR; Acosta EP; Yogev R; Wiznia A; Kraimer J; Graham B; Carey V; Britto P; Jean-Philippe P; Moye J; Watson D
    Pediatr Infect Dis J; 2009 Feb; 28(2):159-61. PubMed ID: 19106779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
    Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.
    Allavena C; Ferré V; Brunet-François C; Delfraissy JF; Lafeuillade A; Valantin MA; Bentata M; Michelet C; Poizot-Martin I; Dailly E; Launay O; Raffi F;
    J Acquir Immune Defic Syndr; 2005 Jul; 39(3):300-6. PubMed ID: 15980689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.
    Solas C; Poizot-Martin I; Drogoul MP; Ravaux I; Dhiver C; Lafeuillade A; Allegre T; Mokhtari M; Moreau J; Lepeu G; Petit N; Durand A; Lacarelle B
    Br J Clin Pharmacol; 2004 Apr; 57(4):436-40. PubMed ID: 15025741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
    Puthanakit T; van der Lugt J; Bunupuradah T; Ananworanich J; Gorowara M; Phasomsap C; Jupimai T; Boonrak P; Pancharoen C; Burger D; Ruxrungtham K
    J Antimicrob Chemother; 2009 Nov; 64(5):1080-6. PubMed ID: 19729375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
    Verweel G; Burger DM; Sheehan NL; Bergshoeff AS; Warris A; van der Knaap LC; Driessen G; de Groot R; Hartwig NG
    Antivir Ther; 2007; 12(4):453-8. PubMed ID: 17668553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.
    Robbins BL; Capparelli EV; Chadwick EG; Yogev R; Serchuck L; Worrell C; Smith ME; Alvero C; Fenton T; Heckman B; Pelton SI; Aldrovandi G; Borkowsky W; Rodman J; Havens PL;
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3276-83. PubMed ID: 18625762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz.
    Dailly E; Allavena C; Raffi F; Jolliet P
    Br J Clin Pharmacol; 2005 Jul; 60(1):32-4. PubMed ID: 15963091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lopinavir.
    Hurst M; Faulds D
    Drugs; 2000 Dec; 60(6):1371-9; discussion 1380-1. PubMed ID: 11152017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.
    Ananworanich J; Kosalaraksa P; Hill A; Siangphoe U; Bergshoeff A; Pancharoen C; Engchanil C; Ruxrungtham K; Burger D;
    Pediatr Infect Dis J; 2005 Oct; 24(10):874-9. PubMed ID: 16220084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
    Kityo C; Walker AS; Dickinson L; Lutwama F; Kayiwa J; Ssali F; Nalumenya R; Tumukunde D; Munderi P; Reid A; Gilks CF; Gibb DM; Khoo S;
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2965-73. PubMed ID: 20421406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
    la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C
    Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.
    Ofotokun I; Chuck SK; Binongo JN; Palau M; Lennox JL; Acosta EP
    J Clin Pharmacol; 2007 Aug; 47(8):970-7. PubMed ID: 17615254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.
    Fraaij PL; Neubert J; Bergshoeff AS; van Rossum AM; Hartwig NG; Schroten H; Korn K; Burger DM; de Groot R; Niehues T
    Antivir Ther; 2004 Apr; 9(2):297-9. PubMed ID: 15134193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.